Brooks Laboratories has announced that its subsidiary, Brooks Steriscience Limited (BSL), has approved a significant corporate restructuring initiative. The plan involves a composite scheme of arrangement and amalgamation encompassing five pharmaceutical entities, aiming to consolidate sterile injectable manufacturing operations under OneSource Specialty Pharma Limited.

Key Merger Details

The approved scheme involves the merger of:

1. Steriscience Specialties Private Limited (SSPL)
2. Brooks Steriscience Limited (BSL)
3. Steriscience Pte Limited (Steriscience SG)
4. Strides Pharma Services Private Limited (SPSPL)
5. OneSource Specialty Pharma Limited (OneSource)

Financial Metrics of Key Entities

Share Exchange Ratios

The merger will be executed through share exchanges:

• 48 Brooks Steriscience shares for every 10 Steriscience Specialties shares
• 137 OneSource shares for every 10 Brooks Steriscience shares

Impact on Shareholding

Post-merger, OneSource's promoter shareholding is expected to increase from 29.77% to 36.17%, while public shareholding will decrease from 70.23% to 63.83%.

Strategic Rationale

The consolidation is designed to:

1. Strengthen business capabilities in the contract development and manufacturing operations (CDMO) sector
2. Create operational synergies and enhance shareholder value
3. Offer a broader product and service portfolio
4. Leverage unified talent pools and diversified technical expertise
5. Improve operational efficiency and cost savings
6. Expand geographical footprint, including the addition of a European Union site

Regulatory Approvals

The scheme requires approvals from:

• Shareholders and creditors of the involved entities
• Stock exchanges (BSE Limited and National Stock Exchange of India Limited)
• Securities and Exchange Board of India (SEBI)
• National Company Law Tribunal
• Singapore High Court
• Other relevant regulatory authorities

Additional Corporate Actions

In a separate announcement, Brooks Laboratories Limited, the parent company of Brooks Steriscience, held its 23rd Annual General Meeting (AGM). Key resolutions passed include:

• Adoption of annual financial statements
• Reappointment of Mr. Bhushan Singh Rana as a director
• Appointment of Sharma Sarin & Associates as Secretarial Auditors for a five-year term
• Approval for entering into arrangements including sale, merger, demerger, or other forms of restructuring
• Approval for the disposal/transfer of investment held in Brooks Steriscience Limited under any restructuring scheme

The merger scheme and additional corporate actions signal a significant strategic shift for Brooks Steriscience and its associated entities, aiming to create a more integrated and competitive pharmaceutical manufacturing operation in the sterile injectables space.

Brooks Laboratories Limited , a prominent player in the pharmaceutical sector, has announced its unaudited financial results for the first quarter of fiscal year 2026, ending June 30, 2025. The company has demonstrated a remarkable turnaround, posting a significant profit and substantial revenue growth.

Financial Highlights

• Net Profit: Brooks Laboratories reported a net profit of Rs. 265.06 lakhs for Q1 FY26, a stark contrast to the loss of Rs. 21.23 lakhs in the same quarter of the previous year.
• Revenue: The company's revenue from operations surged to Rs. 2,551.19 lakhs, marking a 42.3% increase from Rs. 1,793.29 lakhs in Q1 FY25.
• Total Income: Total income rose to Rs. 2,572.89 lakhs, up from Rs. 1,800.22 lakhs year-over-year.

Consolidated Performance

On a consolidated basis, Brooks Laboratories' performance was even more impressive:

• Consolidated Net Profit: The company posted a significantly higher net profit of Rs. 958.48 lakhs.
• Joint Venture Contribution: A substantial portion of the consolidated profit came from the company's share in its jointly controlled entity, Brooks Steriscience Limited, which contributed Rs. 693.42 lakhs.

Brooks Steriscience Limited Performance

Brooks Steriscience Limited, the jointly controlled entity, reported strong results:

• Revenue: Recorded revenue from operations of Rs. 3,230.70 lakhs.
• Licensing Income: Included a substantial licensing income of Rs. 2,083.56 lakhs.
• Profit: Achieved a profit after tax of Rs. 1,415.14 lakhs for the quarter.

Earnings Per Share

• Basic EPS: Improved to Rs. 0.90 from negative Rs. 0.08 in the previous year's quarter.

Management Commentary

The Board of Directors reviewed and approved these results at their meeting held on August 13, 2025.

Segment Information

Brooks Laboratories operates in one reportable business segment: Pharmaceuticals.

Balance Sheet Highlight

As of the latest reported period, the company's paid-up equity share capital stands at Rs. 2,945.72 lakhs, with a face value of Rs. 10 per share.

The robust financial performance of Brooks Laboratories in Q1 FY26 reflects a strong recovery and growth trajectory for the company. The significant contributions from its joint venture, Brooks Steriscience Limited, particularly in licensing income, have played a crucial role in boosting the consolidated results. As the pharmaceutical sector continues to evolve, Brooks Laboratories appears well-positioned to capitalize on market opportunities and drive further growth.